Bandages removed from paws of bobcat burned in Eaton Fire
A bobcat found dehydrated and burned on all four paws during the Eaton Fire in January has made several steps forward in its recovery, officials said recently.
The female bobcat was found in Sierra Madre as the deadly and destructive wildfire raged through the hillsides and nearby communities.
'Our veterinary and wildlife teams cared for her over the coming weeks, changing the bandages on her paws regularly (under sedation) and nursing her back to health,' a Facebook post by Pasadena Human stated last week.
Staff minimized their contact with the injured animal while keeping up treatments and allowing the wounds to heal.
'We are so proud of our staff for providing top-notch care while keeping wildlife wild,' the post read.
After showing the ability to walk comfortably without the bandages, the bobcat was placed at the California Wildlife Center to continue its recovery in an outdoor space before hopefully being returned to the wild.
'The Eaton Fire had a devastating impact on wild animals, but being a part of their recovery gives us hope for the future of our local ecosystem,' Pasadena Humane stated.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
18 hours ago
- New York Post
Freak accident at New Hampshire beach sends teen to ICU as mom warns of waterfront danger
A teenager remains in intensive care after suffering severe injuries in a freak diving accident at Hampton Beach. The incident happened on Monday afternoon in Hampton Beach, New Hampshire, where 19-year-old Aiden Sloan and his cousins were playing in the water to beat the heat. 'He was diving into the water into the waves, I've done it a thousand times, and I think it was more shallow than he expected,' Hampton Beach Fire Chief Michael McMahon told Fox News Digital. Sloan's mom, Melina Burton, echoed McMahon and described the ordeal to Fox News Digital and what life has been like since she got word of her son's injury. 'They were diving into the waves like kids do,' Burton described. 'And there was a sandbar that nobody could have known was there, so he dove through a wave, and he hit the sandbar head-on.' Burton shared that Sloan's cousins also saw something had gone terribly wrong and dragged him to the beach, where they realized he wasn't breathing. 5 Aidan Sloan is pictured in the ICU with a neck brace after his diving injury on June 23, 2025. Aiden's Recovery/Facebook 'He was just, like, not moving at all,' one of Sloan's cousins told NBC10 Boston when the accident happened. 'It was like we were carrying a dead body.' Burton said her son had been completely knocked out and if it was not for his cousins, he might not be alive today. 'They're actually really great kids, and they're handling it so well. I did check in with both of them. Michael, the one that actually pulled Aiden out of the water, was here yesterday. And I said, 'Can I give you a hug?'' Burton said. 'I said, 'I am so, so grateful to you for rescuing my boy and pulling him out of the water,' because he probably would not even be here today if you had not done that. So I will forever be grateful.' 5 Sloan smiles from his hospital bed on June 27, 2025. Aiden's Recovery/Facebook 5 Sloan made progress in his recovery, sitting in a chair twice on June 28, 2025. Aiden's Recovery/Facebook McMahon added that he had gone out on a similar call years ago, in nearly the exact same situation. 'So it didn't shock me, but it's not a regular occurrence for us, certainly. And it is unfortunate,' McMahon said. 'Sometimes, we go to calls and people are doing dumb things and drugs and alcohol and this was not how we saw this. This was just a kid at the beach because it was hot, and he got hurt in a terribly unfortunate way.' A GoFundMe page has been set up for Sloan, where he is described as having suffered from a broken neck. 5 A GoFundMe page has been set up for Sloan, where he is described as having suffered from a broken neck. Aiden's Recovery/Facebook 'He misjudged the depth of some water at Hampton and, as a result, broke his neck,' the post read. 'He is unable to move his legs and hands at this point but is able to move his arms. His mom, Melina, is a single mom and will need to be by her boy's side as he recovers.' Burton said it is too soon to tell if there is any permanent damage and said Sloan is just trying to be strong and take each day as it comes. 'The doctor met with him this morning just to kind of explain to him, one, the surgery that they did on him, and two, what exactly his injuries were. When they explained it to him the first time, he was so drowsy that he didn't really understand,' Burton said. 'So they came back in this morning, they said that he has two things going for him. One, the fact that he's 19, young and strong, and two, that they were able to operate on him within 12 hours of the injury. So the prognosis we don't know yet, there's a lot of different factors.' Sloan, who is also a chef at a restaurant inside the Nash Casino, is receiving support from his employer, who is donating a portion of sales to his medical expenses. 'A member of our Greenleaf family, Aiden Sloan, unfortunately suffered a serious neck injury while having a fun day at Hampton beach earlier this week,' Greenleaf Milford wrote in a post on their Facebook page. 'Aiden joined our Greenleaf family at a young age, and we watched him grow as a person and a cook over the years and he and his family have our full love and support during these difficult times.' Sloan is expected to remain in the hospital for several weeks before going to a rehab facility, Burton said, and is hopeful things turn around. 5 Sloan, who is also a chef at a restaurant inside the Nash Casino, is receiving support from his employer, who is donating a portion of sales to his medical expenses. Aiden's Recovery/Facebook 'They (doctors) ask him multiple times a day if he can move his hands and his fingers, if he could move his feet and toes, and if he can lift his knees. Or if he can feel anything in his midsection, and he gets very defeated and hopeless when he can't,' Burton explained. 'And he doesn't understand why they keep asking him to try these things. So he's very tearful. He's very emotional today, which for anybody who knows Aiden, it is not who he is at all. He is always smiling and joking and happy. And even when, you know, life isn't going so great for him, he is still always just trying to make people laugh. So to see him so defeated and hopeless right now is really heartbreaking.'
Business Wire
a day ago
- Business Wire
ELV Deadline: Rosen Law Firm Urges Elevance Health, Inc. (NYSE: ELV) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that Elevance Health, Inc. (NYSE: ELV) Misled Investors Regarding its Business Operations. According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that, with the Medicaid redetermination process nearly complete, defendants represented to investors that they were closely monitoring cost trends associated with the redetermination process and that the premium rates Elevance was negotiating with states were sufficient to address the risk and cost profiles of those patients staying on Medicaid programs. While defendants acknowledged that Medicaid expenses were rising, they repeatedly assured investors that this was adequately reflected in Elevance's guidance for the year. These representations were materially false or misleading. In truth, the redeterminations were causing the acuity and utilization of Elevance's Medicaid members to rise significantly, as the members being removed from Medicaid programs were, on average, healthier than those who remained eligible for the programs. This shift was occurring to a degree that was not reflected in Elevance's rate negotiations with the states or in its financial guidance for 2024. When the true details entered the market, the lawsuit claims that investors suffered damages. What Now: You may be eligible to participate in the class action against Elevance Health, Inc. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by July 11, 2025. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Rosen Law Firm: Some law firms issuing releases about this matter do not actually litigate securities class actions. Rosen Law Firm does. Rosen Law Firm is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses, improving corporate governance structures, and holding company executives accountable for their wrongdoing. Since its inception, Rosen Law Firm has obtained over $1 billion for shareholders. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome.
Business Upturn
2 days ago
- Business Upturn
Pliant Therapeutics Provides Update on BEACON-IPF
Bexotegrast development in IPF discontinued Clinical oncology program and early-stage programs continue Recent workforce and operational changes align with next steps SOUTH SAN FRANCISCO, Calif., June 27, 2025 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that following the review of data from the recently terminated BEACON-IPF Phase 2b/3 clinical trial, the Company has discontinued development of bexotegrast in idiopathic pulmonary fibrosis (IPF). BEACON-IPF Trial Update BEACON-IPF was a randomized, double-blind, placebo-controlled, global Phase 2b/3 clinical trial evaluating patients with IPF. In March of this year, Pliant announced the voluntary discontinuation of BEACON-IPF following a prespecified data review and recommendation by the trial's independent Data Safety Monitoring Board (DSMB), as well as a secondary review and recommendation by an outside expert panel, citing an imbalance in IPF-related adverse events. Following an analysis of the full safety and efficacy data from the BEACON-IPF trial, the Company is discontinuing development of bexotegrast in IPF. Results showed that at doses of 160 mg and 320 mg, bexotegrast demonstrated an unfavorable risk-benefit profile. Compared to placebo, bexotegrast-treated participants showed an increased risk of experiencing adverse events associated with IPF disease progression, defined as events of worsening of IPF and acute IPF exacerbation, respiratory-related hospitalization, and/or all-cause mortality. The average time to disease progression for bexotegrast-treated participants was 33 weeks, suggesting that the safety risk may not be apparent with shorter dosing duration as was the case in the prior INTEGRIS-IPF Phase 2a trial. At Week 12, bexotegrast 160 mg and 320 mg treatment groups demonstrated improvements in forced vital capacity (FVC) decline of 72 mL (p<0.05) and 46 mL (p>0.05), respectively, compared to placebo. At Week 24, bexotegrast 160 mg and 320 mg treatment groups demonstrated improvements in FVC decline of 58 mL (p>0.05) and 8 mL (p>0.05), respectively, compared to placebo. The full results from BEACON-IPF will be submitted for future publication. 'Although the decision to discontinue bexotegrast in IPF is disappointing for us and the many patients in need of new treatment options, we believe it is the right decision to protect patient safety,' said Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer of Pliant. 'We sincerely thank all patients, their caregivers, the study investigators and their research teams who were part of the BEACON-IPF clinical program for their extensive efforts.' Oncology Phase 1 Enrollment Continues PLN-101095 is an oral, small molecule, dual selective inhibitor of αvβ8 and αvβ1 integrins, designed to block TGF-β activation in the tumor microenvironment. PLN-101095 is currently undergoing a Phase 1 open-label trial as monotherapy and in combination with pembrolizumab in patients with solid tumors that are resistant to immune checkpoint inhibitors. In March, the Company announced interim results from this trial showing that PLN-101095 was generally well tolerated with confirmed partial responses in 50% of patients at highest dose tested to date, across multiple tumor types. The trial is currently enrolling the fifth of five planned dose cohorts. Early Programs Supported by Proprietary Platform The Company's drug discovery platform consists of a proprietary library of over 15,000 integrin binding molecules, a comprehensive screening assay system (binding, integrin confirmation, ligand-induced internalization) and an advanced live human tissue program. The Company believes in the broad applicability of the platform across multiple disease areas including delivery of drug payloads to cells utilizing integrin receptor-binding molecules as tissue-specific delivery and internalization mechanisms. About Pliant Therapeutics, Inc. Pliant Therapeutics is a clinical-stage biopharmaceutical company and leader in the discovery and development of integrin-based therapeutics. Pliant is conducting a Phase 1 study for PLN-101095, a small molecule, dual-selective inhibitor of α v ß 8 and α v ß 1 integrins, that is being developed for the treatment of solid tumors. In addition, Pliant has received regulatory clearance for the conduct of a Phase 1 study of PLN-101325, a monoclonal antibody agonist of integrin α 7 β 1 targeting muscular dystrophies. Pliant's early-stage platform includes preclinical research focused on tissue-specific delivery and internalization of drug payloads utilizing integrin receptor-binding molecules. For additional information, please visit: Follow us on social media X, LinkedIn and Facebook. Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as 'may,' 'will,' 'expect,' 'anticipate,' 'estimate,' 'intend,' and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These statements include those regarding development plans for PLN-101095, PLN-101325 and the Company's proprietary platform; and the Company's efforts to align its workforce and operations for its next steps. Because such statements deal with future events and are based on our current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Pliant Therapeutics could differ materially from those described in or implied by the statements in this press release. These forward-looking statements are subject to risks and uncertainties, including those related to the development and commercialization of our product candidates, including any delays in our ongoing or planned preclinical or clinical trials, the impact of current macroeconomic, geopolitical and marketplace conditions on our business, operations, clinical supply and plans, our reliance on single-source third parties located in foreign jurisdictions, including China, for critical aspects of our development operations, the risks inherent in the drug development process, the risks regarding the accuracy of our estimates of expenses and timing of development, our capital requirements and the need for additional financing, including the availability of additional term loans under our loan facility, and our ability to obtain and maintain intellectual property protection for our product candidates. These and additional risks are discussed in the sections titled 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operations' in our Quarterly Report on Form 10-Q for the period ended March 31, 2025 which are available on the SEC's website at Unless otherwise noted, Pliant is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. Investor and Media Contact: Christopher KeenanVice President, Investor Relations and Corporate CommunicationsPliant Therapeutics, Inc. [email protected]
